Group One Trading’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.4M | Sell |
411,800
-929,400
| -69% | -$29.9M | 0.03% | 684 |
|
|
2025
Q4 | $47.2M | Buy |
1,341,200
+473,000
| +54% | +$16.8M | 0.08% | 227 |
|
|
2025
Q3 | $22.8M | Buy |
868,200
+336,100
| +63% | +$10M | 0.04% | 449 |
|
|
2025
Q2 | $14.1M | Buy |
532,100
+235,500
| +79% | +$6.2M | 0.03% | 609 |
|
|
2025
Q1 | $7.16M | Sell |
296,600
-257,800
| -47% | -$8.15M | 0.02% | 817 |
|
|
2024
Q4 | $22.3M | Sell |
554,400
-120,300
| -18% | -$6.86M | 0.05% | 342 |
|
|
2024
Q3 | $42.7M | Buy |
674,700
+359,200
| +114% | +$21.1M | 0.12% | 114 |
|
|
2024
Q2 | $16.7M | Sell |
315,500
-261,200
| -45% | -$17.1M | 0.06% | 259 |
|
|
2024
Q1 | $47.3M | Sell |
576,700
-203,500
| -26% | -$9.05M | 0.18% | 66 |
|
|
2023
Q4 | $14.5M | Buy |
780,200
+434,100
| +125% | +$5.68M | 0.04% | 483 |
|
|
2023
Q3 | $3.83M | Sell |
346,100
-470,000
| -58% | -$6.72M | 0.01% | 1109 |
|
|
2023
Q2 | $13.2M | Buy |
816,100
+109,000
| +15% | +$2.28M | 0.04% | 386 |
|
|
2023
Q1 | $11.8M | Buy |
707,100
+382,000
| +118% | +$3.95M | 0.04% | 394 |
|
|
2022
Q4 | $3.06M | Buy |
325,100
+198,600
| +157% | +$887K | 0.01% | 1479 |
|
|
2022
Q3 | $344K | Sell |
126,500
-28,500
| -18% | -$93.3K | ﹤0.01% | 3603 |
|
|
2022
Q2 | $448K | Sell |
155,000
-22,600
| -13% | -$55.9K | ﹤0.01% | 3534 |
|
|
2022
Q1 | $533K | Sell |
177,600
-212,200
| -54% | -$761K | ﹤0.01% | 3738 |
|
|
2021
Q4 | $1.79M | Sell |
389,800
-340,700
| -47% | -$1.91M | ﹤0.01% | 2727 |
|
|
2021
Q3 | $4.59M | Buy |
730,500
+104,200
| +17% | +$644K | 0.01% | 1785 |
|
|
2021
Q2 | $3.75M | Buy |
626,300
+157,600
| +34% | +$936K | ﹤0.01% | 1978 |
|
|
2021
Q1 | $2.96M | Buy |
468,700
+327,200
| +231% | +$2.3M | ﹤0.01% | 2048 |
|
|
2020
Q4 | $797K | Sell |
141,500
-178,300
| -56% | -$1.08M | ﹤0.01% | 2847 |
|
|
2020
Q3 | $1.86M | Sell |
319,800
-44,600
| -12% | -$307K | 0.01% | 1665 |
|
|
2020
Q2 | $2.63M | Sell |
364,400
-69,200
| -16% | -$460K | 0.01% | 1266 |
|
|
2020
Q1 | $2.03M | Buy |
433,600
+154,600
| +55% | +$950K | 0.02% | 1038 |
|
|
2019
Q4 | $2.24M | Sell |
279,000
-11,100
| -4% | -$80.9K | 0.02% | 1210 |
|
|
2019
Q3 | $2M | Sell |
290,100
-1,700
| -0.6% | -$12.6K | 0.02% | 1222 |
|
|
2019
Q2 | $2.42M | Buy |
291,800
+54,600
| +23% | +$467K | 0.02% | 937 |
|
|
2019
Q1 | $2.36M | Sell |
237,200
-11,700
| -5% | -$97.9K | 0.03% | 826 |
|
|
2018
Q4 | $1.9M | Sell |
248,900
-321,900
| -56% | -$3.85M | 0.02% | 1071 |
|
|
2018
Q3 | $9.94M | Buy |
570,800
+317,300
| +125% | +$3.78M | 0.08% | 287 |
|
|
2018
Q2 | $2.41M | Buy |
253,500
+225,500
| +805% | +$1.5M | 0.02% | 1003 |
|
|
2018
Q1 | $122K | Buy |
+28,000
| New | +$155K | ﹤0.01% | 3126 |
|
Other funds holding VKTX
VCM
VPM
Group One Trading's VKTX Position: Q1 2026 in Review
Group One Trading increased its Viking Therapeutics (VKTX) stake by 47% in Q1 2026, buying an estimated $2.19M and bringing the position to 211,817 shares worth $6.89M. The position accounts for 0.01% of the portfolio, ranked #1077.
Group One Trading first reported a position in VKTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $16.7M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Group One Trading held 211,817 shares of Viking Therapeutics worth $6.89M as of Q1 2026.
- Group One Trading bought 68,202 Viking Therapeutics shares in Q1 2026, an estimated $2.19M.
- Viking Therapeutics made up 0.01% of Group One Trading's portfolio in Q1 2026, its #1077 holding.
- Group One Trading first reported a position in Viking Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Group One Trading's Viking Therapeutics position peaked at $16.7M in Q3 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.